

Open Peer Review on Qeios

Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Quadrivalent Human Papillomavirus (types 6, 11, 16, 18)</u>
<u>Recombinant Vaccine</u>. NCI Thesaurus. Code C61087.

A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.

Qeios ID: O00BT7 · https://doi.org/10.32388/O00BT7